September 13, 2024FDA Approves Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq), Similar to Ocrevus®

[bxrmom]

The U.S. Food and Drug Administration recently approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq, Genentech) as a twice-a-year healthcare professional (HCP)-administered approximately 10-minute subcutaneous (SC, under the skin) injectable disease-modifying therapy.This medication is approved for people living with both relapsing forms of MS, including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses) and primary progressive MS.

More info continued here:

nationalmssociety.org/news-...

[lbenmaor]

Thank you for this info. Leslie

[CatsandCars]

This could be really good for people who don't live near an infusion center, or have time for long infusions.

[bxrmom in reply to CatsandCars]

That is exactly what I was thinking!

[CatsandCars in reply to bxrmom]

They were probably losing market share to Kesimpta, although to me the side effects some people get seem off putting. But everyone is different, and having more choices is really good for patients. 😊

[Tazmanian]

Thank you

[Irishgirl76]

🙏 THANKS! Have you watched GRETCHEN HAWLEY. NEW PIPE - 307.

Restore myelin? Keep researching and reporting. Love ❤️

[Mark1499]

I’m taking Tysabri, let me know how it goes

Mark